Champions Oncology Inc (NASDAQ:CSBR) was up 8% during mid-day trading on Tuesday . The company traded as high as $11.80 and last traded at $12.49. Approximately 9,202 shares were traded during mid-day trading, a decline of 94% from the average daily volume of 144,876 shares. The stock had previously closed at $11.57.

A number of equities research analysts recently issued reports on CSBR shares. ValuEngine upgraded Champions Oncology from a “hold” rating to a “buy” rating in a research note on Tuesday, June 5th. Janney Montgomery Scott started coverage on Champions Oncology in a research note on Monday, July 9th. They issued a “buy” rating on the stock. Craig Hallum initiated coverage on Champions Oncology in a research note on Tuesday, July 17th. They issued a “buy” rating and a $12.00 price objective on the stock. Finally, Zacks Investment Research raised Champions Oncology from a “hold” rating to a “strong-buy” rating and set a $12.00 target price for the company in a report on Monday. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $11.33.

The firm has a market cap of $116.82 million, a price-to-earnings ratio of -96.64 and a beta of 0.11.

Champions Oncology (NASDAQ:CSBR) last posted its earnings results on Thursday, September 13th. The biotechnology company reported $0.04 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.01 by $0.03. The business had revenue of $6.23 million during the quarter, compared to analyst estimates of $5.85 million. Champions Oncology had a negative return on equity of 124.56% and a negative net margin of 1.63%. sell-side analysts predict that Champions Oncology Inc will post 0.05 EPS for the current year.

A number of hedge funds have recently bought and sold shares of the business. Tocqueville Asset Management L.P. purchased a new position in Champions Oncology during the 2nd quarter valued at about $729,000. Perkins Capital Management Inc. purchased a new position in shares of Champions Oncology during the second quarter worth about $653,000. Essex Investment Management Co. LLC purchased a new position in shares of Champions Oncology during the second quarter worth about $646,000. Renaissance Technologies LLC grew its holdings in shares of Champions Oncology by 63.3% during the second quarter. Renaissance Technologies LLC now owns 100,600 shares of the biotechnology company’s stock worth $638,000 after purchasing an additional 39,000 shares in the last quarter. Finally, BlackRock Inc. purchased a new position in shares of Champions Oncology during the second quarter worth about $104,000. 38.94% of the stock is owned by institutional investors and hedge funds.

Champions Oncology Company Profile (NASDAQ:CSBR)

Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.

Featured Article: Do Tariffs Work?

Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.